Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Drugs reach Non-Hodgkin Lymphoma through trial conditions or approval indications mapped to it or to one of its descendant entities.
45 drugs · 284 active trials
27 drugs · 479 active trials
56 drugs · 2,316 active trials
Outside the funnel: Phase not stated 1 · Withdrawn 1. "Withdrawn" = every approval record for the scope is withdrawn or superseded; "phase not stated" = trials exist but none states a phase.
Data updated 17 hours agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Dexamethasone | Approved | Phase 4 | 259 | 110 | 168 | 832 | 2 | EU, US | Mar 16, 2016 | 1993-03 |
| Rituximab | Approved | Phase 4 | 226 | 93 | 148 | 743 | 2 | EU, US | Nov 26, 1997 | May 8, 1993 |
| Lenalidomide | Approved | Phase 4 | 213 | 78 | 116 | 589 | 4 | US | Dec 27, 2005 | Apr 1, 2002 |
| Cyclophosphamide | Approved | Phase 4 | 209 | 102 | 95 | 660 | 2 | US | Sep 12, 2023 | 1988-03 |
| Daratumumab | Approved | Phase 4 | 121 | 50 | 54 | 218 | 1 | US | Nov 16, 2015 | Jan 31, 2012 |
| Bortezomib | Approved | Phase 4 | 100 | 36 | 93 | 457 | 8 | US | May 13, 2003 | Feb 8, 2001 |
| Doxorubicin | Approved | Phase 4 | 88 | 34 | 55 | 233 | 1 | US | Nov 17, 1995 | May 8, 1993 |
| Pomalidomide | Approved | Phase 4 | 86 | 38 | 41 | 196 | 7 | EU, US | Feb 8, 2013 | 2008-06 |
| Obinutuzumab | Approved | Phase 4 | 79 | 34 | 16 | 142 | 2 | US | Nov 1, 2013 | 2008-01 |
| Carfilzomib | Approved | Phase 4 | 67 | 20 | 26 | 173 | 2 | EU, US | Jul 20, 2012 | 2005-09 |
| Ibrutinib | Approved | Phase 4 | 61 | 18 | 27 | 171 | 5 | US | Nov 13, 2013 | 2010-05 |
| Zanubrutinib | Approved | Phase 4 | 53 | 31 | 9 | 76 | 12 | US | Nov 14, 2019 | 2016-10 |
| Acalabrutinib | Approved | Phase 3 | 53 | 22 | 6 | 71 | 3 | US | Oct 31, 2017 | Jan 30, 2014 |
| Bendamustine | Approved | Phase 4 | 46 | 19 | 41 | 162 | 7 | US | Mar 20, 2008 | 2004-01 |
| Teclistamab | Approved | Phase 4 | 44 | 26 | 11 | 46 | 2 | EU, US | Aug 23, 2022 | Aug 9, 2019 |
| Isatuximab | Approved | Phase 3 | 43 | 17 | 12 | 57 | 2 | EU, US | Mar 2, 2020 | Jan 21, 2015 |
| Epcoritamab | Approved | Phase 3 | 42 | 21 | 6 | 45 | 1 | US | May 19, 2023 | Jun 26, 2018 |
| Belantamab Mafodotin | Approved | Phase 3 | 40 | 14 | 9 | 59 | 3 | EU, US | Jul 23, 2025 | Jul 29, 2014 |
| Methotrexate | Approved | Phase 4 | 39 | 23 | 21 | 135 | 9 | US | Aug 10, 1959 | 1988-03 |
| Pirtobrutinib | Approved | Phase 4 | 36 | 22 | 10 | 41 | 1 | US | Jan 27, 2023 | Mar 15, 2019 |
| Elranatamab | Approved | Phase 4 | 35 | 26 | 6 | 38 | 2 | EU, US | Aug 14, 2023 | Aug 9, 2019 |
| Mosunetuzumab | Approved | Phase 3 | 34 | 19 | 5 | 39 | 2 | EU, US | Jun 3, 2022 | Sep 15, 2015 |
| Glofitamab | Approved | Phase 3 | 32 | 14 | 2 | 40 | 1 | EU | Jul 7, 2023 | Feb 21, 2017 |
| Melphalan | Approved | Phase 4 | 31 | 11 | 32 | 230 | 4 | US | Jun 9, 2009 | 1994-01 |
| Pembrolizumab | Approved | Phase 3 | 30 | 13 | 2 | 91 | 1 | US | Sep 4, 2014 | Nov 22, 2013 |
| Polatuzumab Vedotin | Approved | Phase 3 | 28 | 9 | 5 | 45 | 3 | EU, US | Jun 10, 2019 | Mar 22, 2011 |
| Talquetamab | Approved | Phase 3 | 26 | 16 | 5 | 29 | 2 | EU, US | Aug 9, 2023 | Dec 13, 2018 |
| Selinexor | Approved | Phase 4 | 25 | 12 | 6 | 53 | 3 | EU, US | Jul 3, 2019 | Jun 12, 2014 |
| Tafasitamab | Approved | Phase 3 | 24 | 8 | 5 | 34 | 4 | EU, US | Jul 31, 2020 | 2010-09 |
| Elotuzumab | Approved | Phase 3 | 18 | 6 | 13 | 55 | 5 | EU, US | Nov 30, 2015 | 2006-12 |
| Ixazomib | Approved | Phase 4 | 16 | 3 | 7 | 85 | 2 | EU, US | Nov 20, 2015 | 2009-10 |
| Brentuximab Vedotin | Approved | Phase 4 | 15 | 7 | 6 | 54 | 2 | EU, US | Aug 19, 2011 | 2006-08 |
| Linvoseltamab | Approved | Phase 3 | 14 | 11 | 4 | 15 | 1 | EU | Apr 23, 2025 | Jan 23, 2019 |
| Prednisolone | Approved | Phase 3 | 12 | 5 | 12 | 30 | 1 | US | Jun 1, 2006 | 2000-02 |
| Loncastuximab Tesirine | Approved | Phase 3 | 10 | 5 | 2 | 19 | 2 | EU, US | Apr 23, 2021 | 2016-03 |
| Tazemetostat | Approved | Phase 3 | 9 | 2 | 1 | 22 | 2 | US | Jan 23, 2020 | Jun 13, 2013 |
| Pralatrexate | Approved | Phase 4 | 8 | 5 | 5 | 23 | 1 | US | Sep 24, 2009 | 2006-08 |
| Crizotinib | Approved | Phase 4 | 7 | 1 | 0 | 15 | 4 | US | Aug 26, 2011 | Apr 19, 2006 |
| Thalidomide | Approved | Phase 4 | 6 | 0 | 29 | 95 | 3 | EU, US | Jul 16, 1998 | 1998-02 |
| Belinostat | Approved | Phase 3 | 5 | 3 | 2 | 18 | 1 | US | Jul 3, 2014 | 2005-01 |
| Cladribine | Approved | Phase 4 | 5 | 4 | 1 | 14 | 1 | EU | Apr 14, 2004 | 2004-02 |
| Ciltacabtagene Autoleucel | Approved | Phase 2 | 5 | 3 | 0 | 6 | 1 | EU | May 25, 2022 | Jun 29, 2018 |
| Plerixafor | Approved | Phase 3 | 4 | 2 | 3 | 38 | 1 | US | Dec 15, 2008 | 2004-05 |
| Romidepsin | Approved | Phase 3 | 3 | 2 | 3 | 42 | 1 | US | Nov 5, 2009 | Mar 8, 2001 |
| Vorinostat | Approved | Phase 3 | 3 | 0 | 2 | 39 | 1 | US | Oct 6, 2006 | 2005-08 |
| Idecabtagene Vicleucel | Approved | Phase 3 | 2 | 0 | 2 | 9 | 1 | EU | Aug 18, 2021 | Dec 22, 2015 |
| Pentostatin | Approved | Phase 2 | 1 | 0 | 0 | 7 | 1 | US | Oct 11, 1991 | Sep 6, 1994 |
| Denosumab | Approved | Phase 3 | 1 | 0 | 2 | 6 | 2 | US | Aug 29, 2025 | 2005-11 |
| Bexarotene | Approved | Phase 4 | 1 | 1 | 1 | 5 | 3 | EU, US | Dec 29, 1999 | 2001-12 |
| Vinblastine | Approved | Phase 3 | 1 | 1 | 1 | 3 | 1 | US | Apr 29, 1987 | 2003-01 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.